|
The global hypophosphatasia treatment market size reached USD 2.70 Billion in 2022 and is expected to register a revenue CAGR of 4.3% during the forecast period, according to latest analysis by Emergen Research. Increasing government funding for research and development of treatments for rare diseases is a major factor driving the market revenue growth. In addition, increasing regulatory support for the development and approval of new treatments for rare diseases and providing a supportive environment for the development of treatments for hypophosphatasia is another key factor contributing to the market revenue growth. For instance , in 2019, the US spent USD 83 billion on the research & development of new drugs. Moreover, the number of new drugs approved for sale increased by 60% between 2010 and 2019, with a high of 59 new drugs approved in 2018. The report also offers estimations and predictions about the market segment and sub-segments exhibiting promising growth in the forecast timeline. The report also provides deeper insights into the technological advancements, industrial landscape, and emerging product and technological developments in the Hypophosphatasia Treatment market. It offers fruitful insights into the business sphere to help businesses capitalize on the lucrative growth opportunities. Competitive Terrain: The section on the competitive landscape offers valuable and actionable insights related to the business sphere of the Hypophosphatasia Treatment market, covering extensive profiling of the key market players. The report offers information about market share, product portfolio, pricing analysis, and strategic alliances such as mergers and acquisitions, joint ventures, collaborations, partnerships, product launches and brand promotions, among others. The report also discusses the initiatives taken by the key companies to combat the impact of the COVID-19 pandemic. The leading market contenders listed in the report are: Kirin Holdings Company, Limited, Vericel Corporation, Mereo Biopharma Group PLC, Novartis AG, Alexion Pharmaceuticals, Inc., Bayer AG, Pfizer Inc., AM-Pharma BV, Ultragenyx Pharmaceutical, BioMarin Emergen Research has segmented the global Hypophosphatasia Treatment market on the basis of type, application, end-use, and region: Segments Covered in this report are: - Type Outlook (Revenue, USD Billion; 2019-2032)
- Odontohypophosphatasia
- Pseudohypophosphatasia
- Others
- Treatment Type Outlook (Revenue, USD Billion; 2019-2032)
- Enzyme Replacement Therapy
- Medications
- Surgery
- Others
- Distribution Channel Outlook (Revenue, USD Billion; 2019-2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Sales
The various regions analyzed in the report include: - North America (US, Canada)
- Europe (UK, Italy, Germany, France, Rest of EU)
- Asia Pacific (India, Japan, China, South Korea, Australia, Rest of APAC)
- Latin America (Chile, Brazil, Argentina, Rest of Latin America)
- Middle East & Africa (Saudi Arabia, UAE, South Africa, Rest of MEA)
Key Objectives of the Report: - Analysis and estimation of the Hypophosphatasia Treatment Market size and share for the projected period of 2022-2030
- Extensive analysis of the key players of the market by SWOT analysis and Porter's Five Forces analysis to impart a clear understanding of the competitive landscape
- Study of current and emerging trends, restraints, drivers, opportunities, challenges, growth prospects, and risks of the global Hypophosphatasia Treatment Market
- Analysis of the growth prospects for the stakeholders and investors through the study of the promising segments
- Strategic recommendations to the established players and new entrants to capitalize on the emerging growth opportunities
|
发表于 2024-3-22 14:51:26